Role of Mega Dose of Vitamin C in Critical COVID-19 Patients
NCT ID: NCT04682574
Last Updated: 2022-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
278 participants
INTERVENTIONAL
2020-11-02
2022-03-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia
NCT04264533
Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation
NCT04357782
the Effect of High Dose Ascorbic Acid on Critically Ill Patients With ARDS
NCT03780933
Effect of High Dose Intravenous Vitamin C in Severe Pneumonia
NCT05842382
Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation
NCT04342728
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
vitamin C
The dose would be 30 grams a day (10 grams TDS) for 3 days with standard treatment
Vitamin C
mega dose is given to the selected critically ill patients
Placebo
Distill water in the same dose with same standard treatment
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vitamin C
mega dose is given to the selected critically ill patients
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Lahore
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Muhammad Mansoor Hafeez
Doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bahria Town International Hospital
Lahore, Punjab Province, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRBEC/BIH/09-2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.